2-O-Galloylmyricitrin
博飞美科提供的所有产品仅用于科研等非医疗用途，非药品不可食用，不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。如您需要产品COA等资料，可至下方“质量控制”中下载
PA73065
PERFEMIKER
56939-52-7
C28H24O16
616.48
*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!
| 产品名称： |
2-O-没食子酰基杨梅苷,≥98% |
| 英文名称： |
2-O-Galloylmyricitrin |
| 英文别名： |
2"-galloylmyricitrin;2''-galloylmyricitrin;myricetin 3-O-(2''-O-galloyl)-alpha-rhamnopyranoside;myricetin 3-O-alpha-(2''-O-galloyl)rhamnoside;myricetin-3-O-(2''-O-galloyl)-alpha-L-rhamnopyranoside;myricetin-3-O-(2''-O-galloyl)rhamnopyranoside;Myricetin-3-O-(3''-O-galloyl)-α-rhamnopyranoside;Myricetin-3-O-α-L-(2-O-β-D-glucopyranosyl)rhamnopyranoside-7-O-β-D-glucopyranoside;myricitrin 2''-O-gallate |
| 品牌： |
PERFEMIKER |
| CAS号： |
56939-52-7 |
| 分子式： |
C28H24O16 |
| 分子量： |
616.48 |
| 纯度： |
≥98% |
| 详细描述： |
博飞美科的2-O-没食子酰基杨梅苷,≥98%为抑制剂,产品稳定,定制速度快,极大地方便了广大科研客户的使用需求。产品包装为5mg。查询关键词:抑制剂，56939-52-7，2-O-没食子酰基杨梅苷,≥98%，2-O-Galloylmyricitrin，博飞美科，Perfemiker，上海，厂家直销。 |
沪公网安备31011402010658号 
C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d(C(%5bH%5d)(%5bH%5d)%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%5d(%5bH%5d)(C1(%5bH%5d)%5bH%5d)O%5bC%40%5d1(%5bH%5d)C(C2C(%3dC3C(%3dC(C(%5bH%5d)(%5bH%5d)%5bH%5d)C(%3dC(%5bH%5d)C3%3dC(%5bH%5d)C%3d2C(%5bH%5d)(%5bH%5d)%5bC%40%40%5d1(%5bH%5d)%5bC%40%40%5d(%5bH%5d)(C(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bC%40%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(C(%5bH%5d)(%5bH%5d)%5bH%5d)%3dO)O%5bC%40%5d1(%5bH%5d)C(%5bH%5d)(%5bH%5d)%5bC%40%5d(%5bH%5d)(%5bC%40%5d(%5bH%5d)(%5bC%40%40%5d(%5bH%5d)(C(%5bH%5d)(%5bH%5d)%5bH%5d)O1)OC(%5bH%5d)(%5bH%5d)%5bH%5d)O%5bH%5d)O%5bH%5d)O%5bH%5d)%3dO)O%5bH%5d)O%5bH%5d)
C%3d2)F)%3dO)%5bC%40H%5d1C1C%3dNC%3dCC%3d1)%3dO)(F)F)
%3dO)C(COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)COC(CCCC%2fC%3dC%5cC%2fC%3dC%5cC%2fC%3dC%5cCCCCC)%3dO)
O)O)C%2fC%3dC%5cCCC(%3dO)OC)